Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, DMT, 2C-B, 2C-E, 2C-T-7, DOx series show less
2C-T-2
4-(ethylthio)-2,5-dimethoxyphenethylamine
2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine) is a synthetic psychedelic of the phenethylamine class. It is structurally related to 2C-B, differing by a sulfur-containing group where 2C-B has bromine at the 4-position. It activates serotonin receptors in the brain, producing the visual, emotional, and cognitive shifts of classical psychedelic experience.[1]
2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine) is a synthetic psychedelic of the phenethylamine class. It belongs to the thio-substituted 2C series, distinguished from 2C-B and 2C-I by the sulfur-containing group at the 4-position. 2C-T-2 is a 5-HT₂A receptor agonist, producing its effects by activating serotonin signaling pathways that alter perception and cognition.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, DMT, 2C-B, 2C-E, 2C-T-7, DOx series show less
Alexander Shulgin synthesized 2C-T-2 in 1981 and named it one of his six most rewarding phenethylamine compounds.[2] After his 1991 book PiHKAL made the synthesis public, it spread through research chemical markets. The European Union controlled it in 2003[3] and the United States followed in 2012; it is now illegal in most major jurisdictions.
Subjective effects include geometric visual patterns, emotional intensification, introspective depth, time alteration, and heightened sensory richness. The experience is more emotionally textured and introspective than 2C-B — richly layered rather than primarily visual, with a heavy physical undertone. Nausea, body discomfort, and anxious dysphoria in difficult settings are common.
2C-T-2 produces no physical dependence, and no lethal dose has been established.[4] The main danger is a drug interaction: monoamine oxidase enzymes break down the compound,[5] so MAO inhibitors block clearance and allow serotonin to reach potentially fatal levels. No controlled human studies have been published — what is known rests on Shulgin's self-experimentation and analogy to related serotonergic psychedelics.
History[edit]
Discovery
Shulgin synthesized 2C-T-2 in 1981 during systematic research into sulfur-substituted phenethylamines.[2] Nine participants joined the first group session at 12–16 mg on December 5 that year.[2] He ranked it one of his "magical half-dozen" — the six phenethylamines he considered most significant, alongside mescaline, DOM, 2C-B, 2C-E, and 2C-T-7.[2]
Research chemical era
When PiHKAL was published in 1991, Shulgin's synthesis routes became public, and 2C-T-2 appeared on research chemical markets through the late 1990s and early 2000s.[6][1] Its place in the "magical half-dozen" and shorter duration relative to 2C-T-7 made it especially sought after.
Prohibition
The European Union named 2C-T-2 in legislation in 2003, requiring member states to impose criminal controls.[3] The United States added it to Schedule I in 2012 via the FDASIA.[7] Japan controlled it in 2008; Canada followed in 2016.citation needed
The "2C" prefix denotes two carbon atoms in the chain connecting the phenyl ring to the amine — a structural feature distinguishing these compounds from amphetamine analogs. The "T" marks a sulfur-containing (thioether) group at the 4-position, and "2" specifies the ethyl group attached to that sulfur. Shulgin's "magical half-dozen" designation was personal, not pharmacological — a ranking of which experiences he found most rewarding. This status gave 2C-T-2 a lasting reputation within psychedelic communities as one of the richest phenethylamine experiences, despite no formal clinical validation.
Chemistry[edit]
Structural class
2C-T-2 belongs to the 2C-T series — a family of synthetic phenethylamines with a sulfur-containing (thioether) group at the 4-position of the phenyl ring.[8]
The thioether distinguishes it from halogen-substituted relatives like 2C-B (bromine) and 2C-I (iodine), and gives the 2C-T compounds a different metabolic profile. Other series members include 2C-T-7 and 2C-T-4.
Molecular structure
| Molecular formula | C₁₂H₁₉NO₂S |
| Molecular weight | 241.35 g/mol |
Pharmacology[edit]
Mechanism of action
2C-T-2 activates serotonin receptors with high affinity and high efficacy,[7][1] producing psychedelic effects through the same signaling cascade shared by other classical serotonergic psychedelics.[9] It does not meaningfully affect dopamine, serotonin, or norepinephrine transporters,[1] which distinguishes it from stimulants and empathogens. Behavioral studies in rodents confirm it follows established structure-activity patterns for this class.[6][10]
2C-T-2 is a monoamine oxidase substrate, not a MAO inhibitor. Some secondary sources incorrectly classify it as a monoamine oxidase inhibitor. Published evidence establishes that MAO-A and MAO-B are the primary enzymes responsible for breaking down 2C-T-2.[5] While weak MAO-A inhibition has been documented for some 2C-series compounds at concentrations far above those relevant to psychedelic effects,[11] this is pharmacologically negligible at typical doses. The clinical significance: MAO inhibitors are dangerous with 2C-T-2 because they block its clearance, not because 2C-T-2 itself inhibits MAO.
Pharmacokinetics
No human pharmacokinetic studies have been published. MAO-A and MAO-B are the primary enzymes that break down 2C-T-2,[5] with CYP2D6 playing a minor role. Duration of effects is 6–8 hours, based on Shulgin's self-experimentation.[2]
Neuroscience[edit]
Where it acts
No neuroimaging studies have been published for 2C-T-2. As a high-efficacy serotonin receptor activator, it is expected to act on neurons in the prefrontal cortex, where serotonergic psychedelics enhance excitatory signaling — the proposed mechanism behind hallucinogenic perception.[12] Evidence from LSD, psilocybin, and DMT suggests this disrupts the brain's normal filtering of sensory input and increases crosstalk between otherwise separate networks.
Why it matters
One prominent theory proposes that psychedelics reduce the brain's reliance on top-down predictions, letting raw sensory experience override expectation. 2C-T-2's serotonin receptor activation is consistent with this framework, though it has never been tested directly on this compound. Serotonergic psychedelics also appear to promote new brain connections — whether 2C-T-2 produces this effect at relevant doses is unknown.
Whether 2C-T-2 produces the same brain network disruption as tryptamine psychedelics is unknown. Its near-equal activity at two serotonin receptor subtypes and its interaction with rat TAAR1[1] introduce variables absent in psilocybin or LSD. No data exist on how well the compound crosses into the brain relative to other phenethylamines, and the 6–8 hour duration remains unexplained without human pharmacokinetic data.
Subjective Effects[edit]
2C-T-2 produces a richly layered, introspective experience. At common doses, the mind turns inward: thought becomes dense and associative, emotions deepen, and visual surfaces develop texture and geometry. It is not primarily a visual psychedelic — the emotional and cognitive depth is the defining quality, with visuals playing a supporting role.
Relative to 2C-B, 2C-T-2 is heavier and more emotionally involving, with a more pronounced body load — a bodily heaviness characteristic of the thioether 2C-T series. Compared to 2C-T-7, the experience is shorter and generally less physically taxing, with a more manageable time commitment.
Synthesized by Alexander Shulgin in 1981, 2C-T-2 was one of six phenethylamines he designated his "magical half-dozen" — a personal ranking of the most phenomenologically rewarding compounds in the class.[2] It circulated through research chemical markets after the 1991 publication of PiHKAL but drew early regulatory action, with the European Union controlling it in 2003[3] and the United States following in 2012. It is now a controlled substance in most major jurisdictions, with no clinical trial registered or published.
Subjective effects include geometric visual patterns, time alteration, thought connectivity, and emotional intensification. The experience is reported as richly layered and introspective — more emotionally textured than 2C-B, with a heavier somatic undertone characteristic of the thioether 2C-T series. Nausea, body load, and anxious dysphoria in unfavorable settings are common unsought effects.
2C-T-2 produces no physical dependence, and no lethal dose has been established in any species.[4] The primary risk is pharmacokinetic: metabolism depends on MAO-A and MAO-B,[5] making co-administration with monoamine oxidase inhibitors a potentially fatal interaction through impaired clearance and serotonin accumulation. No controlled human studies exist — the current understanding rests on Shulgin's self-experimentation, in vitro pharmacology, and class-level extrapolation from related serotonergic psychedelics.
History[edit]
Discovery
Shulgin synthesized 2C-T-2 in 1981 as part of a systematic exploration of sulfur-substituted phenethylamines.[2] The first group assay involved nine participants at oral doses of 12–16 mg on December 5, 1981.[2] Published as entry #40 in PiHKAL (1991), Shulgin designated it one of his "magical half-dozen" — six phenethylamines he considered most significant, alongside mescaline, DOM, 2C-B, 2C-E, and 2C-T-7.[2]
Research chemical era
Following ''PiHKAL'''s publication, 2C-T-2 appeared on research chemical markets in the late 1990s and early 2000s, sold alongside 2C-T-7, 2C-B, and 2C-I through online vendors. Its inclusion in Shulgin's "magical half-dozen" and shorter duration relative to 2C-T-7 made it particularly sought after. No clinical trial has been registered — its role in contemporary science is as a structure-activity relationship data point for phenethylamine psychedelics.[6][1]
Prohibition
The European Union was the first major jurisdiction to specifically control 2C-T-2, via Council Decision 2003/847/JHA on 27 November 2003, naming it alongside 2C-T-7, 2C-I, and TMA-2.[3] The United States followed nine years later, adding 2C-T-2 to Schedule I via the FDASIA in 2012.[7] Japan controlled it in 2008, and Canada placed it in Schedule III in 2016.citation needed
The "2C" prefix denotes two carbon atoms in the ethylamine chain — the phenethylamine backbone — distinguishing these compounds from amphetamine analogs that carry an alpha-methyl group. The "T" marks the thioether substituent at the 4-position, and "2" specifies the ethyl group on sulfur. Shulgin's "magical half-dozen" designation, a personal rather than pharmacological ranking, gave 2C-T-2 a lasting reputation within psychedelic communities as one of the most rewarding phenethylamine experiences — a status that persists despite the absence of any formal clinical validation.
Chemistry[edit]
Structural class
2C-T-2 belongs to the 2C-T series of substituted phenethylamines, defined by 2,5-dimethoxy substitution on the phenyl ring and a thioalkyl group at the 4-position. The thioether linkage distinguishes the 2C-T compounds from halogen-substituted 2C drugs like 2C-B (4-bromo) and 2C-I (4-iodo), introducing different electronic and steric properties that modulate receptor binding and metabolism.[8] Other members of the thio series include 2C-T-7 (isopropylthio) and 2C-T-4.
Molecular structure
| Molecular formula | C₁₂H₁₉NO₂S |
| Molecular weight | 241.35 g/mol |
The molecule comprises a 2,5-dimethoxyphenyl ring bearing an ethylthio (–SCH₂CH₃) group at the 4-position and a 2-aminoethyl side chain. The sulfur atom forms a thioether bond that gives the 2C-T series its distinct metabolic profile — the thioether can be oxidized to sulfoxide and sulfone metabolites, a pathway absent in halogenated 2C compounds.
Stereochemistry
2C-T-2 has no chirality center. The phenethylamine backbone lacks an alpha-methyl group, so the compound exists as a single constitutional isomer without enantiomeric forms. This contrasts with amphetamine-derived psychedelics like the DOx series, where chirality at the alpha carbon produces R- and S-enantiomers with differing potencies.
Structure-activity relationships
Within the 2C-T series, varying the alkyl group on sulfur modulates potency, duration, and experiential character. 2C-T-7 (isopropylthio) is longer-acting; 2C-T-2 (ethylthio) occupies a moderate position. The thioether substituent increases lipophilicity relative to bromo or iodo analogs, consistent with the observation that 2C-T-2 shows lower cell toxicity than its NBOMe derivative (25T2-NBOMe).[9]
Pharmacology[edit]
Mechanism of action
2C-T-2 activates serotonin 5-HT₂A and 5-HT₂C receptors with high affinity and high efficacy.[7][1] Its psychedelic effects are produced through the Gq-protein signaling pathway at the 5-HT₂A receptor — the same cascade responsible for the effects of other serotonergic psychedelics.[10] Rodent head-twitch response data confirm that 2C-T-2 closely follows established structure-activity relationships for the serotonergic psychedelic class.[6][11]
The compound does not meaningfully interact with dopamine, serotonin, or norepinephrine transporters,[1] distinguishing it from stimulants and empathogens that act through monoamine release or reuptake inhibitor. It activates rat TAAR1 but does not interact with the human form of this receptor.[1]
2C-T-2 is a monoamine oxidase substrate, not a MAO inhibitor. Some secondary sources incorrectly classify it as a monoamine oxidase inhibitor. Published evidence establishes that MAO-A and MAO-B are the primary enzymes responsible for breaking down 2C-T-2.[5] While weak MAO-A inhibition has been documented for some 2C-series compounds at concentrations far above those relevant to psychedelic effects,[12] this is pharmacologically negligible at typical doses. The clinical significance: MAO inhibitors are dangerous with 2C-T-2 because they block its clearance, not because 2C-T-2 itself inhibits MAO.
Pharmacokinetics
No human pharmacokinetic studies have been published. Half-life, bioavailability, peak plasma concentration, and volume of distribution remain entirely uncharacterized in humans.
The primary metabolic enzymes are MAO-A and MAO-B, with a minor role for CYP2D6.[5] Additional metabolic steps include removal of methyl groups (O-demethylation) and conversion to aldehyde intermediates.[5][13]
In rat models, the major urinary metabolites are the N-acetylated-sulfoxide and S-methylated-N-acetylated-sulfoxide.[14] This metabolic profile differs from 2C-T-7, whose principal metabolite involves a different oxidation pathway — a difference attributable to the distinct shape of the ethylthio versus isopropylthio group.
Oral duration of action is 6–8 hours based on Shulgin's self-experimentation.[2] No pharmacokinetic explanation for this duration has been published.
Neuroscience[edit]
Where it acts
No neuroimaging data have been published for 2C-T-2. As a high-efficacy serotonin 2A receptor agonist, the compound is expected to act primarily on layer V pyramidal neurons in the prefrontal cortex, where serotonergic psychedelics enhance excitatory glutamate signaling — a mechanism proposed as the neurophysiological basis for hallucinogenic perceptual distortions.[15]
Class-level evidence from LSD, psilocybin, and DMT indicates that 5-HT₂A activation produces dissolution of default mode network connectivity (correlated with ego dissolution), disrupted thalamic filtering of sensory information, increased cross-talk between normally segregated brain networks, and higher neural signal diversity.
Why it matters
The REBUS model proposes that psychedelics reduce the brain's reliance on top-down predictions, allowing raw sensory information greater influence on conscious experience. 2C-T-2's 5-HT₂A activation is consistent with this framework, though no direct neural entropy measurement has been conducted under the compound.
Serotonergic psychedelics also promote structural brain connectivity through intracellular signaling cascades — the "psychoplastogen" hypothesis. Whether 2C-T-2 produces these neuroplastic effects at relevant concentrations is untested; its phenethylamine scaffold and thioether group could influence cell penetration differently from tryptamine psychoplastogens.
Whether 2C-T-2 produces the same brain network disruption patterns as tryptamine psychedelics is unknown. Its near-equal binding at 5-HT₂A and 5-HT₂C receptors and its interaction with rat TAAR1[1] introduce pharmacological variables absent in psilocybin or LSD, which could modify the neural response in ways not yet measured.
Subjective Effects[edit]
2C-T-2 produces an experience described as richly layered and introspective — more emotionally textured and cognitively involving than a purely visual psychedelic. The experiential character shifts substantially across the dose range: lower doses produce gentle visual enhancement and mood lift, while common-to-strong doses open into structured geometric visuals, deep emotional processing, and altered time perception. Set and setting exert unusually strong influence — identical doses can produce deeply rewarding introspection or anxious dysphoria depending on context.
Relative to 2C-B, 2C-T-2 is more introspective and emotionally complex, with a heavier body load characteristic of the thioether-substituted 2C-T series. Compared to 2C-T-7, the experience is shorter and generally less physically taxing, with a more manageable time commitment.
Effect Grid
At common doses (12–20 mg oral), the full psychedelic experience manifests: structured open- and closed-eye visuals including geometric patterning, color shifting, drifting and morphing of surfaces, and enhanced pattern recognition. Time distortion becomes pronounced. Thought acceleration and conceptual thinking intensify, often producing novel associations and insights. Emotional amplification is significant — music, social interactions, and aesthetic experiences carry heightened meaning.
Body load is characteristic of the 2C-T series: internal pressure, mild gastrointestinal discomfort, temperature dysregulation, and muscular tension. Nausea is most common during the come-up phase. Pupil dilation is marked. Tachycardia and mild hypertension are possible.
Duration is 6–8 hours with residual stimulation extending beyond the primary experience. Sleep is unlikely for at least 8 hours post-ingestion. Functional impairment is significant throughout.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Brightness alteration · Geometry · Visual breathing · Holotropic state · Touch enhancement · Tracers · After-images · Symmetrical texture repetition · Depth perception distortion · Environmental patterning · Light sensitivity · Perspective distortion · Sound sensitivity · Visual morphing · Auditory distortion · Auditory enhancement · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual diffraction · Visual haze / noise · Visual melting · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Synesthesia · Vestibular distortion · Visual magnification · Olfactory enhancement · Object transformations · External hallucinations · Object activation · Visual recursion · Visual scenery slicing · Internal hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations
Touch enhancement · Tracers · After-images · Symmetrical texture repetition · Depth perception distortion · Environmental patterning · Light sensitivity · Perspective distortion · Sound sensitivity · Visual morphing · Auditory distortion · Auditory enhancement · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual diffraction · Visual haze / noise · Visual melting · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Synesthesia · Vestibular distortion · Visual magnification · Olfactory enhancement · Object transformations · External hallucinations · Object activation · Visual recursion · Visual scenery slicing · Internal hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations
Spontaneous body sensations · Body high · Wakefulness · Nausea · Appetite suppression · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Body schema distortion · Dizziness · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Vibrations / buzzing · Diarrhea · Bodily lightness · Breathing alteration · Dehydration sensation · Excessive sweating · Headache · Involuntary body movements · Motor control impairment · Sexual arousal enhancement · Trembling · Abnormal heartbeat · Bruxism · Nystagmus (eye wobbles) · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Nausea · Appetite suppression · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Body schema distortion · Dizziness · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Vibrations / buzzing · Diarrhea · Bodily lightness · Breathing alteration · Dehydration sensation · Excessive sweating · Headache · Involuntary body movements · Sexual arousal enhancement · Trembling · Abnormal heartbeat · Bruxism · Nystagmus (eye wobbles) · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Novelty enhancement · Immersion enhancement · Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Analysis enhancement · Memory suppression · Thought acceleration · Thought loops · Confusion · Cognitive fatigue · Cognitive impairment · Creativity enhancement · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Multiple thought streams · Thought disorganization · Humor enhancement · Memory replays · Synchronicity · Focus enhancement · Information processing enhancement · Motivation enhancement · Delusions
Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Analysis enhancement · Memory suppression · Thought acceleration · Thought loops · Confusion · Cognitive fatigue · Cognitive impairment · Creativity enhancement · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Multiple thought streams · Thought disorganization · Humor enhancement · Memory replays · Synchronicity · Focus enhancement · Information processing enhancement · Motivation enhancement
Anxiety · Simultaneous emotions · Anxiety suppression · Catharsis · Dysphoria · Irritability
Dysphoria · Irritability
Trust enhancement · Communication enhancement · Sociability enhancement · Depersonalization · Flow state · Ego inflation · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution
Flow state · Ego inflation · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution
Time cessation
Transpersonal visions · Entity contact
Recursive awareness
Timeline
First alerts appear as mild mood shift, slight color brightening, and faint bodily awareness. Easily dismissed as placebo at lower doses.
Psychedelic effects build progressively: color saturation increases, surface textures begin to shift, and nausea or body load characteristic of the 2C-T series may emerge. Anxiety during this phase is common.
Full psychedelic state with structured open- and closed-eye visuals, pronounced time distortion, thought acceleration, and emotional amplification. Visual geometry and environmental morphing are most intense. The balanced 5-HT₂A/5-HT₂C activation produces a characteristically rich visual and emotional profile.
Intensity gradually recedes while perceptual and cognitive alterations persist at reduced magnitude. Body load typically resolves. Emotional depth remains accessible without the overwhelming intensity of the peak.
Visual effects fade to subtle trailing and color enhancement. Cognitive clarity returns progressively. Residual stimulation and mild mood elevation persist.
Subtle mood elevation, reflective thinking, and mild residual visual sensitivity may persist for several hours. Sleep may remain elusive for 2–4 hours after subjective effects resolve.
⚠ Do not drive or operate heavy machinery for at least 10 hours after ingestion, or until after a full night of sleep.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No lethal dose has been established for 2C-T-2 in any species, and no confirmed fatal overdose specifically attributed to the compound appears in published literature.[4] Clinical presentations of serious 2C-class intoxication include hallucinations, agitation, high blood pressure, rapid heart rate, seizures, and dangerously elevated body temperature.[4]
At least five deaths have been attributed to 2C compounds collectively, with extreme agitation, overheating, and cardiovascular collapse as the primary fatal pattern.[4] Individual attribution is complicated by polydrug use and inconsistent toxicological testing.
In vitro neurotoxicity
Laboratory studies found concentration-dependent cell damage from 2C-T-2 — including mitochondrial dysfunction and depleted cellular defenses — at concentrations far exceeding estimated human brain exposure at typical doses.[13] Clinical relevance at normal use levels is unknown.
Psychological risks
No controlled studies have assessed psychological adverse events from 2C-T-2. Class-level risks include acute anxiety and panic, transient psychotic episodes at strong-to-heavy doses, HPPD (HPPD — a condition where visual disturbances persist long after the drug has cleared), and destabilization of pre-existing psychiatric conditions.
Agitation, aggression, and violence have been documented in clinical presentations of 2C-class intoxication.[4]
Tolerance & dependence
Tolerance builds rapidly through downregulation in the frontal cortex,[14] extending to other serotonergic psychedelics including LSD and the broader 2C class.[14] Full reset takes approximately 7 days.inferred
No physical dependence or withdrawal has been documented. 2C-T-2 does not act on dopamine transporters,[1] meaning it does not engage the reward circuitry responsible for compulsive drug-seeking.
Drug Interactions
MAO inhibitors are the most dangerous interaction. The body relies on MAO-A and MAO-B to clear 2C-T-2.[5] Blocking those enzymes causes 2C-T-2 to accumulate and serotonin levels to rise dangerously.
The result is serotonin syndrome — dangerously high body temperature, muscle rigidity, involuntary muscle movements, cardiovascular instability, and altered consciousness. This applies to irreversible MAOIs (phenelzine, tranylcypromine), reversible ones (moclobemide), and MAO-B drugs (selegiline) at higher doses.
SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, duloxetine) add serotonergic stimulation, elevating serotonin syndrome risk.[4][15] Fluoxetine and paroxetine also slow a minor metabolic pathway (CYP2D6).
Lithium combined with serotonergic psychedelics carries increased seizure risk.safety citation needed
Triptans (sumatriptan, rizatriptan) add serotonergic stimulation.[15]
Tramadol combines serotonin reuptake inhibitor with seizure threshold reduction, creating dual risk.
CNS depressants (alcohol, benzodiazepines, opioids) can mask signs of toxicity — elevated body temperature and rapid heart rate — while adding their own risks, including respiratory depression.[4]
Contraindications
7 knownAbsolute:
- Concurrent monoamine oxidase inhibitor therapy, including dietary supplements containing harmine or harmaline[5]
- Personal or family history of psychotic disorders
- Lithium therapysafety citation needed
Relative:
- Bipolar disorder — risk of precipitating manic episodes
- Cardiovascular disease — 2C-class intoxication presents with high blood pressure and rapid heart rate[4]
- Epilepsy or seizure history[4]
- Concurrent SSRI/SNRI therapy
- Pregnancy — no reproductive toxicity data exist
- CYP2D6 poor metabolizer status[5]
Harm Reduction[edit]
Forms & Identification
2C-T-2 is most commonly sold as a white to off-white hydrochloride salt powder. Because 2C-T series compounds are visually indistinguishable from each other and from other white-powder phenethylamines, reagent testing cannot confirm specific identity — it can only confirm the phenethylamine class.
A positive Marquis reaction and a Mecke result consistent with thio-substituted phenethylamines narrow the field, but GC-MS or a drug-checking service is the only reliable way to confirm the exact compound and dose.
The active dose range (12–25 mg) is narrow enough that small weighing errors meaningfully shift the experience. A milligram-precision scale (0.001 g) is essential — estimating by eye is not safe at this potency.
Guidelines
- Test the substance. Use reagent kits to confirm the phenethylamine class, and use a drug-checking service if available to verify identity and dose.
- Weigh precisely. Use a milligram-precision scale. Never estimate doses by eye.
- Start low. Begin at the lower end of the common dose range if unfamiliar with 2C-T-2 — experience with other psychedelics does not predict individual response.
- Oral route only. Insufflation causes intense nasal pain and a more abrupt, harder-to-manage onset.
- Eat lightly beforehand. A light meal 2–3 hours before reduces nausea without significantly delaying onset.
- Arrange a sitter. A sober, trusted person who can provide reassurance and call for help if needed.
- Prepare the environment. Comfortable temperature, accessible water, a quiet space to retreat to, calming music available.
- Do not redose early. Onset may take 60–90 minutes. Taking more before the full effects arrive risks overshooting the intended dose.
- Have a plan for difficulty. Know in advance what to do if anxiety escalates — change of room, music, breathing, or asking the sitter for grounding.
Set & Setting
2C-T-2 is notably sensitive to psychological and environmental context. Identical doses can produce deeply introspective, emotionally rich experiences or anxious, dysphoric ones depending on mindset and surroundings. A calm, familiar environment with trusted companions significantly reduces the likelihood of difficult experiences.
The 6–8 hour duration means committing an entire evening or day. Avoid situations requiring sharp judgment, driving, or social obligations during and for several hours after the experience.
Aftercare & integration. The days following a 2C-T-2 experience may include emotional sensitivity, fatigue, and residual shifts in perception or mood. These typically resolve within 24–48 hours.
Journaling or discussing the experience with a trusted person can help process emotionally intense material. If the experience surfaced difficult psychological content, give it time before drawing conclusions — psychedelic experiences often need days or weeks to integrate.
Seek professional support if persistent anxiety, depersonalization, disturbing visual phenomena, or difficulty returning to baseline functioning continue beyond a week. A therapist experienced with psychedelic integration can help contextualize and work through the material.
Recovery & Support
2C-T-2 does not produce physical dependence, and compulsive use is rare due to rapid tolerance. Psychological reliance on psychedelic experiences — using them to avoid rather than process difficult emotions — can develop with any substance in this class.
If psychedelic use is becoming a pattern that interferes with daily functioning, relationships, or emotional stability, support is available through harm reduction organizations, psychedelic integration circles, and mental health professionals. The Fireside Project (62-FIRESIDE / 623-473-7433) offers peer support for people processing psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Most difficult 2C-T-2 experiences involve anxiety, confusion, or nausea and resolve without medical intervention. Seek immediate help if any of the following occur:
- Seizures or uncontrollable muscle rigidity
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Complete loss of contact with reality combined with self-harm risk
- Loss of consciousness
Immediate steps:
- 1. Call emergency services. Do not wait to see if symptoms improve.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. If body temperature is dangerously high, begin active cooling: remove excess clothing, apply cool water, fan the skin.
- 4. Do not restrain the person physically unless there is immediate danger — restraint worsens overheating.
- 5. Do not induce vomiting.
- 6. Stay with the person until help arrives.
What to tell the dispatcher:
Name the substance (2C-T-2, a synthetic psychedelic), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency from prosecution — getting medical attention is the priority.
Legal Status[edit]
2C-T-2 is controlled in most major jurisdictions, with no approved medical use anywhere.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Added via FDASIA in 2012; DEA code 7385. Prior to 2012, subject to potential prosecution under the Federal Analogue Act given structural similarity to Schedule I 2C-B.[7] |
| European Union | Controlled (Council Decision 2003/847/JHA) | Specifically named alongside 2C-T-7, 2C-I, and TMA-2 on 27 November 2003. Member states required to enact criminal control measures.[3] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the phenethylamine generic clause.citation needed |
| Australia | Schedule 9 (Prohibited Substance) | Listed in the Poisons Standard; no permitted use outside approved research.citation needed |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Placed on Schedule III effective October 31, 2016 (Item 35).citation needed |
| Japan | Designated substance | Controlled since 2008.citation needed |
Analog act considerations
In the United States before 2012, 2C-T-2 could have been prosecuted under the Federal Analogue Act given its structural similarity to 2C-B (Schedule I since 1995). The 2012 FDASIA scheduling made that argument moot for 2C-T-2 specifically, but it remains relevant for novel thio-substituted phenethylamines not yet explicitly scheduled.
Legal status varies by jurisdiction and changes over time. This information reflects published records as of the article date and is not legal advice. Verify current status with local legal resources before making any decisions.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No lethal dose has been established for 2C-T-2 in any species, and no confirmed fatal overdose attributed specifically to the compound appears in published literature.[4] Clinical presentations of 2C-class intoxication include hallucinations, agitation, aggression, high blood pressure, rapid heart rate, seizures, and dangerously elevated body temperature.[4]
At least five deaths have been attributed to 2C compounds collectively, with excited delirium — a state of extreme agitation, overheating, and cardiovascular collapse — as the predominant fatal presentation.[4] Individual substance attribution in these cases is imprecise due to polysubstance use and inconsistent toxicological analysis.
In vitro neurotoxicity
Laboratory studies demonstrated concentration-dependent cell damage from 2C-T-2, involving mitochondrial dysfunction, energy depletion, and reduced cellular antioxidant defenses — though notably not through oxidative stress.[9] These effects occurred at concentrations far exceeding estimated human brain exposure at typical doses, and clinical relevance at normal use levels is unknown.
2C-T-2 showed lower toxicity than its NBOMe structural analog (25T2-NBOMe), consistent with differences in lipophilicity.[9]
Psychological risks
No controlled studies have assessed psychological adverse events from 2C-T-2. Class-level risks for serotonergic phenethylamine psychedelics include acute psychological distress (anxiety, panic, paranoia), transient psychotic episodes at strong-to-heavy doses, HPPD (HPPD), and destabilization of pre-existing psychiatric conditions including psychotic disorders and bipolar mania.
Agitation, aggression, and violence have been documented in clinical presentations of 2C-class intoxication,[4] consistent with a serotonergic sympathomimetic profile.
Tolerance & dependence
Tolerance develops rapidly through downregulation of 5-HT₂A receptors in the frontal cortex.[16] Cross-tolerance extends to other serotonergic psychedelics, including LSD and the broader 2C class.[16] Tolerance builds over approximately 3 days with full reset at approximately 7 days.inferred
No physical dependence or withdrawal has been documented for 2C-T-2 or for serotonergic psychedelics generally. The absence of DAT activity[1] is consistent with negligible engagement of reward circuitry.
Drug Interactions
MAO inhibitors are the most dangerous interaction. Because MAO-A and MAO-B are 2C-T-2's primary metabolic enzymes,[5] co-administration with any MAOI — irreversible (phenelzine, tranylcypromine), reversible (moclobemide), or MAO-B selective (selegiline at higher doses) — substantially reduces clearance. The resulting elevated levels compound the serotonergic load, creating high risk for serotonin syndrome: a potentially fatal condition marked by dangerously high body temperature, muscle rigidity, involuntary muscle movements, cardiovascular instability, and altered consciousness.
SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, duloxetine) create additive serotonergic stimulation, elevating serotonin syndrome risk.[4][17] Fluoxetine and paroxetine additionally inhibit CYP2D6, a minor metabolic pathway for 2C-T-2.
Lithium combined with serotonergic psychedelics carries increased seizure risk at the class level.safety citation needed
Triptans (sumatriptan, rizatriptan) add serotonergic stimulation.[17]
Tramadol combines serotonin reuptake inhibitor with seizure threshold reduction, creating dual risk.
CNS depressants (alcohol, benzodiazepines, opioids) may mask signs of toxicity — elevated body temperature, rapid heart rate — while adding independent risks such as respiratory depression.[4]
Contraindications
7 knownAbsolute:
- Concurrent monoamine oxidase inhibitor therapy, including dietary supplements containing harmine or harmaline[5]
- Personal or family history of psychotic disorders
- Lithium therapysafety citation needed
Relative:
- Bipolar disorder — risk of precipitating manic episodes
- Cardiovascular disease — 2C-class intoxication presents with high blood pressure and rapid heart rate[4]
- Epilepsy or seizure history[4]
- Concurrent SSRI/SNRI therapy
- Pregnancy — no reproductive toxicity data exist
- CYP2D6 poor metabolizer status — minor pathway, but combined with other clearance-reducing factors could elevate exposure[5]
Harm Reduction[edit]
Forms & Identification
2C-T-2 is most commonly encountered as a white to off-white hydrochloride salt powder. Because the 2C-T series compounds are visually indistinguishable from each other and from other white-powder phenethylamines, reagent testing alone cannot confirm identity — it can only indicate the phenethylamine class. A positive Marquis reaction and a Mecke result consistent with thio-substituted phenethylamines narrow the field, but quantitative analysis (such as a drug-checking service or GC-MS) is the only reliable method to confirm the specific compound and dose.
The active dose range for 2C-T-2 (12–25 mg) is narrow enough that small weighing errors can meaningfully shift the experience. A milligram-precision scale (0.001 g) is essential — volumetric dosing or eyeballing powder is not safe at this potency.
Guidelines
- Test the substance. Use reagent kits to confirm phenethylamine class, and use a drug-checking service if available to verify identity and dose.
- Weigh precisely. Use a milligram-precision scale. Never estimate doses by eye.
- Start low. Begin at the lower end of the common dose range if unfamiliar with 2C-T-2 specifically — experience with other psychedelics does not predict individual response to this compound.
- Oral route only. Insufflation produces intense nasal pain and a more abrupt, harder-to-manage onset. Oral administration allows a gentler come-up.
- Eat lightly beforehand. A light meal 2–3 hours before reduces nausea without significantly delaying onset.
- Arrange a sitter. A sober, trusted person who can provide reassurance and call for help if needed.
- Prepare the environment. Comfortable temperature, accessible water, quiet space to retreat to, calming music available.
- Do not redose early. Onset may take 60–90 minutes. Taking more before the full effects manifest risks overshooting the intended dose.
- Have a plan for difficulty. Know in advance what you will do if anxiety escalates — change of room, music, breathing exercises, or asking the sitter for grounding.
Set & Setting
2C-T-2 is notably sensitive to psychological and environmental context. Identical doses can produce deeply introspective, emotionally rich experiences or anxious, dysphoric ones depending on mindset and surroundings. A calm, familiar environment with trusted companions significantly reduces the likelihood of difficult experiences.
First-time users and those uncertain about their psychological readiness should start at the lower end of the common dose range. The 6–8 hour duration means committing an entire evening or day — avoid situations requiring sharp judgment, driving, or social obligations during and for several hours after the experience.
Aftercare & integration. The days following a 2C-T-2 experience may include emotional sensitivity, fatigue, and residual shifts in perception or mood. These typically resolve within 24–48 hours.
Journaling or discussing the experience with a trusted person can help process emotionally intense material. If the experience surfaced difficult psychological content, give it time before drawing conclusions — psychedelic experiences often need days or weeks to integrate fully.
Seek professional support if persistent anxiety, depersonalization, disturbing visual phenomena, or difficulty returning to baseline functioning continue beyond a week. A therapist experienced with psychedelic integration can help contextualize and process the material.
Recovery & Support
2C-T-2 does not produce physical dependence, and compulsive use patterns are rare due to rapid tolerance. However, psychological reliance on psychedelic experiences — using them to avoid engaging with difficult emotions rather than processing them — can develop with any substance in this class.
If psychedelic use is becoming a pattern that interferes with daily functioning, relationships, or emotional stability, support is available through harm reduction organizations, psychedelic integration circles, and mental health professionals. The Fireside Project (62-FIRESIDE / 623-473-7433) offers peer support for people processing psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Most difficult 2C-T-2 experiences involve anxiety, confusion, or nausea and resolve without medical intervention. Seek immediate help if any of the following occur:
- Seizures or uncontrollable muscle rigidity
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Complete loss of contact with reality combined with self-harm risk
- Loss of consciousness
Immediate steps:
- 1. Call emergency services. Do not wait to see if symptoms improve.
- 2. Place the person in the recovery position if unconscious but breathing.
- 3. If body temperature is dangerously high, begin active cooling: remove excess clothing, apply cool water, fan the skin.
- 4. Do not restrain the person physically unless there is immediate danger — restraint worsens overheating.
- 5. Do not induce vomiting.
- 6. Stay with the person until help arrives.
What to tell the dispatcher:
Name the substance (2C-T-2, a synthetic psychedelic), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency from prosecution — getting medical attention is the priority.
Legal Status[edit]
2C-T-2 is controlled in most major jurisdictions. The European Union was the first to specifically name it in legislation (2003), preceding US federal scheduling by nine years. The compound has no approved medical use in any jurisdiction and is not subject to any active clinical development program.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Added via FDASIA in 2012; DEA code 7385. Prior to 2012, subject to potential prosecution under the Federal Analogue Act given structural similarity to Schedule I 2C-B.[7] |
| European Union | Controlled (Council Decision 2003/847/JHA) | Specifically named alongside 2C-T-7, 2C-I, and TMA-2 on 27 November 2003. Member states required to enact criminal control measures.[3] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the phenethylamine generic clause.citation needed |
| Australia | Schedule 9 (Prohibited Substance) | Listed in the Poisons Standard; no permitted use outside approved research.citation needed |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Placed on Schedule III effective October 31, 2016 (Item 35).citation needed |
| Japan | Designated substance | Controlled since 2008.citation needed |
Analog act considerations
In the United States prior to 2012, 2C-T-2 could have been prosecuted under the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption, given its structural and pharmacological similarity to 2C-B (Schedule I since 1995). The 2012 FDASIA scheduling rendered the analog argument moot for 2C-T-2 specifically but remains relevant for novel thio-substituted phenethylamines not yet explicitly scheduled.
Frequently asked questions
How long does 2C-T-2 last?
Total duration by route of administration — Oral: 6 – 8 hours; Insufflated: 3 – 5 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 2C-T-2?
Psychedex publishes a dosage table for 2C-T-2 on this page covering these routes of administration: insufflated, oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 2C-T-2?
The highest-severity documented interactions for 2C-T-2: Amphetamines (Lethal), MDMA, Amphetamines (Lethal), MDMA, MDA (Lethal), Psychedelics (Lethal), SNRIs (Lethal). See the interactions section for the full list with mechanisms and severity levels.
Is 2C-T-2 addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 2C-T-2: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT, 2C-B, 2C-E, 2C-T-7, DOx series. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abHalberstadt AL, Luethi D, Hoener MC, Trachsel D, Brandt SD, Liechti ME (2023) Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines — Psychopharmacology doi:10.1007/s00213-022-06279-2
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abHalberstadt AL, Luethi D, Hoener MC, Trachsel D, Brandt SD, Liechti ME (2023) Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines — Psychopharmacology doi:10.1007/s00213-022-06279-2